Immunosuppression for the prevention and treatment of BOS

Sangeeta M. Bhorade*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Over the past 3 decades, lung transplantation has evolved into a life-saving procedure for patients with end-stage lung disease. During this time, further development of biologic agents and newer immunosuppressive agents has continued to improve outcomes after transplantation. Although there is variability among centers regarding specific immunosuppressive medications, the overall approach to immunosuppressive regimens in lung transplantation is quite uniform and consists of a triple-drug immunosuppressive regimen that includes a calcineurin inhibitor, an antimetabolite, and corticosteroids (CS), with or without a biological agent as induction therapy. However, the discovery and continued development of new immunosuppressive agents that target novel immune pathways provide alternate therapeutic options for lung recipients with progressive decline in pulmonary function. The current goal of immunosuppression is to maintain allograft viability by preventing acute and chronic rejection while decreasing toxicities associated with immunosuppression. This chapter will review the current approach to immunosuppressive medications that are used in the maintenance of allograft stability and the prevention and treatment of bronchiolitis obliterans syndrome (BOS).

Original languageEnglish (US)
Title of host publicationBronchiolitis Obliterans Syndrome in Lung Transplantation
PublisherHumana Press Inc
Pages251-276
Number of pages26
ISBN (Electronic)9781461476368
ISBN (Print)9781461476351
DOIs
StatePublished - Jan 1 2013

Fingerprint

Bronchiolitis Obliterans
Immunosuppressive Agents
Immunosuppression
Lung Transplantation
Biological Factors
Allografts
Therapeutics
Antimetabolites
Lung
Lung Diseases
Adrenal Cortex Hormones
Transplantation
Maintenance
Pharmaceutical Preparations

Keywords

  • Alemtuzumab
  • Azathioprine
  • Basiliximab
  • Belatacept
  • Bortezomib
  • Bronchiolitis obliterans syndrome
  • Corticosteroids
  • Cyclosporine
  • Lung transplant
  • Mycophenolate mofetil
  • Rituximab
  • Tacrolimus
  • Thymoglobulin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bhorade, S. M. (2013). Immunosuppression for the prevention and treatment of BOS. In Bronchiolitis Obliterans Syndrome in Lung Transplantation (pp. 251-276). Humana Press Inc. https://doi.org/10.1007/978-1-4614-7636-8_14
Bhorade, Sangeeta M. / Immunosuppression for the prevention and treatment of BOS. Bronchiolitis Obliterans Syndrome in Lung Transplantation. Humana Press Inc, 2013. pp. 251-276
@inbook{547d3a6139844adeb3c315e0aa76a40c,
title = "Immunosuppression for the prevention and treatment of BOS",
abstract = "Over the past 3 decades, lung transplantation has evolved into a life-saving procedure for patients with end-stage lung disease. During this time, further development of biologic agents and newer immunosuppressive agents has continued to improve outcomes after transplantation. Although there is variability among centers regarding specific immunosuppressive medications, the overall approach to immunosuppressive regimens in lung transplantation is quite uniform and consists of a triple-drug immunosuppressive regimen that includes a calcineurin inhibitor, an antimetabolite, and corticosteroids (CS), with or without a biological agent as induction therapy. However, the discovery and continued development of new immunosuppressive agents that target novel immune pathways provide alternate therapeutic options for lung recipients with progressive decline in pulmonary function. The current goal of immunosuppression is to maintain allograft viability by preventing acute and chronic rejection while decreasing toxicities associated with immunosuppression. This chapter will review the current approach to immunosuppressive medications that are used in the maintenance of allograft stability and the prevention and treatment of bronchiolitis obliterans syndrome (BOS).",
keywords = "Alemtuzumab, Azathioprine, Basiliximab, Belatacept, Bortezomib, Bronchiolitis obliterans syndrome, Corticosteroids, Cyclosporine, Lung transplant, Mycophenolate mofetil, Rituximab, Tacrolimus, Thymoglobulin",
author = "Bhorade, {Sangeeta M.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-7636-8_14",
language = "English (US)",
isbn = "9781461476351",
pages = "251--276",
booktitle = "Bronchiolitis Obliterans Syndrome in Lung Transplantation",
publisher = "Humana Press Inc",

}

Bhorade, SM 2013, Immunosuppression for the prevention and treatment of BOS. in Bronchiolitis Obliterans Syndrome in Lung Transplantation. Humana Press Inc, pp. 251-276. https://doi.org/10.1007/978-1-4614-7636-8_14

Immunosuppression for the prevention and treatment of BOS. / Bhorade, Sangeeta M.

Bronchiolitis Obliterans Syndrome in Lung Transplantation. Humana Press Inc, 2013. p. 251-276.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Immunosuppression for the prevention and treatment of BOS

AU - Bhorade, Sangeeta M.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Over the past 3 decades, lung transplantation has evolved into a life-saving procedure for patients with end-stage lung disease. During this time, further development of biologic agents and newer immunosuppressive agents has continued to improve outcomes after transplantation. Although there is variability among centers regarding specific immunosuppressive medications, the overall approach to immunosuppressive regimens in lung transplantation is quite uniform and consists of a triple-drug immunosuppressive regimen that includes a calcineurin inhibitor, an antimetabolite, and corticosteroids (CS), with or without a biological agent as induction therapy. However, the discovery and continued development of new immunosuppressive agents that target novel immune pathways provide alternate therapeutic options for lung recipients with progressive decline in pulmonary function. The current goal of immunosuppression is to maintain allograft viability by preventing acute and chronic rejection while decreasing toxicities associated with immunosuppression. This chapter will review the current approach to immunosuppressive medications that are used in the maintenance of allograft stability and the prevention and treatment of bronchiolitis obliterans syndrome (BOS).

AB - Over the past 3 decades, lung transplantation has evolved into a life-saving procedure for patients with end-stage lung disease. During this time, further development of biologic agents and newer immunosuppressive agents has continued to improve outcomes after transplantation. Although there is variability among centers regarding specific immunosuppressive medications, the overall approach to immunosuppressive regimens in lung transplantation is quite uniform and consists of a triple-drug immunosuppressive regimen that includes a calcineurin inhibitor, an antimetabolite, and corticosteroids (CS), with or without a biological agent as induction therapy. However, the discovery and continued development of new immunosuppressive agents that target novel immune pathways provide alternate therapeutic options for lung recipients with progressive decline in pulmonary function. The current goal of immunosuppression is to maintain allograft viability by preventing acute and chronic rejection while decreasing toxicities associated with immunosuppression. This chapter will review the current approach to immunosuppressive medications that are used in the maintenance of allograft stability and the prevention and treatment of bronchiolitis obliterans syndrome (BOS).

KW - Alemtuzumab

KW - Azathioprine

KW - Basiliximab

KW - Belatacept

KW - Bortezomib

KW - Bronchiolitis obliterans syndrome

KW - Corticosteroids

KW - Cyclosporine

KW - Lung transplant

KW - Mycophenolate mofetil

KW - Rituximab

KW - Tacrolimus

KW - Thymoglobulin

UR - http://www.scopus.com/inward/record.url?scp=85025129934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025129934&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-7636-8_14

DO - 10.1007/978-1-4614-7636-8_14

M3 - Chapter

SN - 9781461476351

SP - 251

EP - 276

BT - Bronchiolitis Obliterans Syndrome in Lung Transplantation

PB - Humana Press Inc

ER -

Bhorade SM. Immunosuppression for the prevention and treatment of BOS. In Bronchiolitis Obliterans Syndrome in Lung Transplantation. Humana Press Inc. 2013. p. 251-276 https://doi.org/10.1007/978-1-4614-7636-8_14